UNSPSC 51333408: Tefludazine

This classification denotes a serotonin antagonist and dopamine antagonist with the molecular formula C22H24F4N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2XUS19W8FE, chemically known as 1-piperazineethanol, 4-(3-(4-fluorophenyl)-2,3-dihydro-6-(trifluoromethyl)-1h-indel-1-yl)-, trans-(+-)- but generally known as tefludazine, which bears US NIH Compound Identifier 71240. European Medicines Agency schedules Tefludazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10867MIG.

UNSPSC 51333408 Tefludazine, a Commodity code, shows minimal recent activity aligned with its nominal scope. The three most recent state and local opportunities posted under this code involve naloxone procurement, direct-to-manufacturer pharmacy programs, and generic multi-source pharmaceutical distribution—none of which center on tefludazine as a specific product. The code appears to be assigned to pharmaceutical and pharmaceutical-related services more broadly, but the actual buying activity documented does not reflect the single-product classification the code nominates.

The issuing bodies represent a mix of county health departments, state health and human services commissions, and multi-state cooperative purchasing alliances. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023 (note the discrepancy in posted versus due dates in the source). The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, to solicit vendor capabilities for direct-to-manufacturer prescription programs. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 on January 20, 2026, for generic multi-source pharmaceuticals and OTC products with a response deadline of March 26, 2026, serving Minnesota, Oregon, and other participating state and local facilities through authorized wholesalers AmerisourceBergen Drug Corporation (Cencora), Cardinal Health, and Morris & Dickson Co., LLC. Recent activity clusters in Florida, Texas, and Minnesota, with cooperative purchasing expanding the geographic scope to additional states. The code shows no sustained activity specifically tied to tefludazine; business development professionals should verify whether their product or service aligns with actual procurement patterns under this classification before investing pursuit resources.